Literature DB >> 12636232

Pleiotropic functions of erythropoietin.

Ryuzo Sasaki1.   

Abstract

Erythropoietin (EPO) produced by the fetal liver and adult kidney is an essential stimulator of erythropoiesis. EPO production is regulated through hypoxic activation of gene transcription and possibly hypoxia-induced stabilization of its mRNA. In the liver of early embryos in which EPO production poorly responds to hypoxia, retinoic acid may be an important stimulator. In this decade, new sites of EPO production have been found: central nervous system and reproductive organs. These tissues have a paracrine and/or autocrine system of EPO, which is independent of the endocrine system (kidney/bone marrow) in adult erythropoiesis. In the central nervous system, astrocytes are the main producers of EPO, while EPO receptor is expressed in neurons. EPO protects neurons from a various types of damage. The uterine EPO is likely involved in the estrogen-dependent angiogenesis of the endometrial layer. The possible functions of EPO in other tissues and tissue-characteristic regulation of EPO production are also discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12636232     DOI: 10.2169/internalmedicine.42.142

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  28 in total

Review 1.  Molecular targets in spinal cord injury.

Authors:  Stefan Klussmann; Ana Martin-Villalba
Journal:  J Mol Med (Berl)       Date:  2005-08-02       Impact factor: 4.599

Review 2.  JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?

Authors:  Olga V Smirnova; Tatiana Yu Ostroukhova; Roman L Bogorad
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

3.  Erythropoietin enhances immunostimulatory properties of immature dendritic cells.

Authors:  F Rocchetta; S Solini; M Mister; C Mele; P Cassis; M Noris; G Remuzzi; S Aiello
Journal:  Clin Exp Immunol       Date:  2011-06-07       Impact factor: 4.330

4.  PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells.

Authors:  Yuan Xue; Sharon Lim; Yunlong Yang; Zongwei Wang; Lasse Dahl Ejby Jensen; Eva-Maria Hedlund; Patrik Andersson; Masakiyo Sasahara; Ola Larsson; Dagmar Galter; Renhai Cao; Kayoko Hosaka; Yihai Cao
Journal:  Nat Med       Date:  2011-12-04       Impact factor: 53.440

Review 5.  Advances in neuroprotective strategies: potential therapies for intracerebral hemorrhage.

Authors:  Brian Y Hwang; Geoffrey Appelboom; Amit Ayer; Christopher P Kellner; Ivan S Kotchetkov; Paul R Gigante; Raqeeb Haque; Michael Kellner; E Sander Connolly
Journal:  Cerebrovasc Dis       Date:  2010-12-21       Impact factor: 2.762

6.  Cerebral arteriovenous malformation presenting with polycythemia vera: A case report and literature review.

Authors:  Mairaj T Sami; Bradley N Bohnstedt; Eyas M Hattab; Raymond Markham; Aaron A Cohen-Gadol
Journal:  Int J Surg Case Rep       Date:  2013-07-20

7.  Erythropoietin receptor signaling regulates both erythropoiesis and megakaryopoiesis in vivo.

Authors:  Xiaosong Huang; L Jeanne Pierce; George L Chen; Ko-Tung Chang; Gerald J Spangrude; Josef T Prchal
Journal:  Blood Cells Mol Dis       Date:  2009-10-17       Impact factor: 3.039

Review 8.  Survival and proliferative roles of erythropoietin beyond the erythroid lineage.

Authors:  Constance Tom Noguchi; Li Wang; Heather M Rogers; Ruifeng Teng; Yi Jia
Journal:  Expert Rev Mol Med       Date:  2008-12-01       Impact factor: 5.600

9.  Sex differences in the alterations of Na(+), K(+)-ATPase following ischaemia-reperfusion injury in the rat kidney.

Authors:  Andrea Fekete; Adám Vannay; Agota Vér; Barna Vásárhelyi; Veronika Müller; Nengtai Ouyang; György Reusz; Tivadar Tulassay; Attila J Szabó
Journal:  J Physiol       Date:  2003-12-12       Impact factor: 5.182

10.  Erythropoietin deficiency decreases vascular stability in mice.

Authors:  Jing Chen; Kip M Connor; Christopher M Aderman; Lois E H Smith
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.